News | January 09, 2015

CHI Franciscan Health Designated As The First Northwest Accredited Heart Failure System

Healthcare Colloquium was chosen as accreditation body because of framework that enables standardized best practices and coordination of care

heart Failure, CHI Franciscan, Healthcare Colloquium

Image courtesy of PR Newswire


January 9, 2015 — The Healthcare Colloquium announced that CHI Franciscan Health is the first Accredited Heart Failure System in the Northwest.

St. Joseph Medical Center earned recognition as an Accredited Heart Failure Institute.

St. Elizabeth Hospital, St. Francis Hospital, St. Clare Hospital, St. Anthony Hospital and Harrison Medical Center became Accredited Heart Failure Centers.  CHI Franciscan Health is the third Accredited Heart Failure system through The Healthcare Colloquium.

The Healthcare Colloquium's unique heart failure accreditation process builds on the member hospital's prior improvement experience leading to initial heart failure accreditation. Member hospitals work within four established domains of heart failure: community, hospital, clinicians and science using The Healthcare Colloquium's continuum of care model that leads to:  

·  Integration of heart failure care; from antecedents to early diagnosis and advanced care

·  Streamlined processes across the entire continuum of care beginning in the community

·  Enabling individuals to participate in their own care with more independence and less hospitalization

·  Collaboration with other Colloquium member hospitals across the country

For more information:  www.chifranciscan.org


Related Content

News | Heart Failure

Aug. 14, 2025 — Analytics For Life, in collaboration with its U.S. commercial partner CorVista Health, announced they ...

Home August 15, 2025
Home
News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
News | Heart Failure

March 25, 2025 — Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive ...

Home March 25, 2025
Home
News | Heart Failure

March 17, 2025 — Bayer recently announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental new ...

Home March 21, 2025
Home
News | Heart Failure

Jan. 7, 2025 — FIRE1 recently announced it has received Breakthrough Device Designation from the U.S. Food and Drug ...

Home January 07, 2025
Home
News | Heart Failure

Heart failure is a rapidly growing public health issue that can be difficult to manage on a global scale. But there are ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 30, 2024 — Cytokinetics, Inc. recently announced that additional analyses synthesizing data from SEQUOIA-HCM ...

Home October 02, 2024
Home
Subscribe Now